Performance Overview - The company expects a net profit attributable to shareholders of 320 million to 410 million yuan for 2025, representing a year-on-year growth of 28.28% to 64.36%. The non-recurring net profit is projected to be between 290 million and 380 million yuan, with a growth of 35.47% to 77.52% [2] - In January 2026, the production volume was 1,347 units, an increase of 56.81% year-on-year, while the sales volume reached 1,231 units, up 35.72% year-on-year, continuing the trend of an 8.36% increase in sales to 12,363 units in 2025 [3] Strategic Developments - The company has made progress in overseas markets, signing a strategic cooperation agreement for 10,000 units with Saudi Arabia's Absa Had Group in 2025 and winning a bid for 91 buses in Dubai, including 40 electric buses. The company is focusing on "new energy, internationalization, and high-end" strategies to achieve market breakthroughs in various regions [4] Stock Performance - On February 6, 2026, the stock price increased by 5.06% to 12.24 yuan per share, with a cumulative increase of 3.37% over three consecutive days. Institutional holdings include new entries in the top ten circulating shareholders by Huaxia Anyang 6-month holding period mixed A and招商量化精选股票发起式A in the third quarter of 2025 [5] Industry Policy Context - The bus industry benefited from the new energy bus replacement cycle and increased export demand in 2025, but it may return to a more subdued state in 2026. The company focuses on new energy and large and medium-sized buses, with sales of new energy large and medium-sized buses over 6 meters increasing by 142.2% year-on-year in the first 11 months of 2025 [6]

智通财经2月7日讯（记者 汪斌）汽车智能化与电动化浪潮之下，内饰功能升级与传感器用量激增，为上游连接件市场带来结构性机遇。作为汽车定制化连 接件领域的"隐形冠军"，浙江华远（301535.SZ）近几个月来产线满负荷运转，订单持续增长。 智通财经记者获悉，行业头部企业近期均产销两旺。国内汽车紧固件头部企业超捷股份（301005.SZ）相关人士对智通财经记者表示，目前公司主业订单情 况较好；长华集团（605018.SH）方面也对智通财经记者表示，公司紧固件业务的订单和客户都较为稳定，工厂每天两班倒、三班倒，平常加班较多。在"年 产20亿件汽车高强度紧固件生产线建设项目（一期）"投产前，长华集团的紧固件产能基本饱和，订单会看情况挑着接。据悉，公司年产20亿件汽车高强度 紧固件生产线建设项目于2024年12月量产，目前产能处于爬坡状态，整体产能利用率较高。 对于2026年的营收情况，公司预计仍可保持一定增长。如此积极的表态，似乎正显示出管理层对未来业绩增长的信心。这份信心究竟来源于哪？带着这样的 疑问，智通财经记者于近日调研走访了浙江华远。 年新增定点项目近千个，产能趋紧 "目前公司整体产能利用率在90%以上，相对比 ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price range of HKD 9.15 to HKD 9.57, corresponding to a PE ratio of 12.6 to 13.2 for 2026, indicating a potential upside of 23% to 29% [4]. Core Insights - The company is a leading player in the apparel manufacturing industry, with a diverse product range and a strong growth outlook. Revenue is expected to increase by 13% year-on-year to USD 2.47 billion in 2024, with net profit rising by 23% to USD 200 million [1][15]. - The company has a well-established international presence, with approximately 80,000 employees and an annual output of over 470 million garments. The production capacity is set to expand further to meet growing order demands [2][15]. - The company has a stable customer base, with significant contributions from major clients like Fast Retailing Group, which accounts for over one-third of its order revenue. The sportswear segment is experiencing rapid growth, driving overall revenue increases [3][15]. Summary by Sections Company Overview - The company is a leading apparel manufacturer with a wide range of products including casual wear, sportswear, outdoor clothing, denim, intimate apparel, sweaters, and knitted fabrics. It has a robust growth trajectory with expected revenue and profit increases in the coming years [1][15]. Capacity Expansion - The company is actively expanding its integrated supply chain and production capacity to match order demands. It has a global workforce and is investing in automation and vertical integration to enhance efficiency and market share [2][4][15]. Orders and Client Relationships - The company has a diversified client structure, with major clients contributing significantly to its revenue. The sportswear category is a key growth driver, supported by long-term partnerships with leading brands [3][15]. Financial Analysis and Profit Forecast - The company is projected to achieve revenues of USD 2.74 billion in 2025, with a year-on-year growth of 10.9%. Net profit is expected to reach USD 232 million, reflecting a 15.7% increase [5][3][15]. Dividend Policy - The company has a stable cash flow, with a dividend payout ratio historically between 30% and 50%. The payout ratio is expected to increase to 70% in 2024, indicating potential for further dividend growth [4][27].

Core Insights - The letter from Ganli Pharmaceutical reflects on the challenges and achievements of 2025, emphasizing the importance of resilience and commitment to quality in the pharmaceutical industry [4][5] - The company projects a net profit of 1.1 billion to 1.2 billion yuan for 2025, representing a year-on-year growth of 78.96% to 95.23%, driven by domestic market recovery and international revenue growth [4][5] - Ganli Pharmaceutical is committed to internationalization, with significant milestones achieved in various global markets, including the approval of its insulin product in Ethiopia and a partnership in Brazil [5][6] Financial Performance - The expected net profit for 2025 is between 1.1 billion and 1.2 billion yuan, marking a substantial increase compared to the previous year [4] - The growth is attributed to the recovery of the domestic market, structural optimization, and sustained international revenue [4] Internationalization Efforts - Ganli Pharmaceutical has made significant strides in international markets, with a systematic approach to registration and collaboration [5][6] - The company has entered the Sub-Saharan African market with its insulin product and has established a long-term supply agreement in Brazil worth no less than 3 billion yuan [5] - The approval of Ondibta® in the EU marks a milestone as the first Chinese third-generation insulin to enter the European market, showcasing the company's alignment with international standards [6] Research and Development - The company continues to invest in R&D, focusing on metabolic diseases with several innovative pipelines advancing to critical clinical stages [6][7] - Ongoing projects include GLP-1 receptor agonists and long-acting insulin formulations, with research findings being published in international academic forums [6][7] Future Outlook - Ganli Pharmaceutical aims to maintain a steady pace in its internationalization strategy while enhancing its R&D capabilities to meet global market demands [7] - The company is committed to contributing to the global biopharmaceutical industry and providing reliable treatment options for patients [7]

我们预计公司25-27 营业收入分别55.6/65.5/78.0 亿元，分别同比增长15%/18%/19%；预计25-27 归母净 利润分别为1.1/3.2/4.6 亿元，分别同比增长-7%/207%/42%，对应当前PE 分别111/36/25X，给予"推荐"评 级。 事件：妙可蓝多于2026 年2 月10 日发公告，公司于2026 年02 月08 日与Saudia Dairy & Foodstuff Company（以下简称"SADAFCO"）签署备忘录。 拟合作沙特领先乳企，国际化迈向新征程。公司于2026 年2 月8 日与沙特阿拉伯上市公司SADAFCO 签 署合作备忘录，拟共同开拓奶酪品类在沙特市场的业务机遇。SADAFCO 成立于1976 年，2024 年营收 55 亿元，市值约135 亿元。双方拟聚焦儿童奶酪零食（特别是奶酪棒）在沙特市场的开发、商业化与分 销，结合妙可蓝多的研发与生产能力，以及SADAFCO 在当地的渠道、运营与消费者偏好数据优势。合 作模式可能包括贸易、品牌许可、特许权使用费或组建合资公司，具体形式待进一步协商。目前本备忘 录为框架性、意向性文件，不具法律约束力，不涉及具体投 ...

Core Viewpoint - The first Dadu Spring Festival Temple Fair will be held from February 17 to 23, 2026, at the National Convention Center Phase II, offering a modern indoor cultural consumption experience that transcends traditional outdoor fairs in winter [1][2]. Group 1: Event Details - The event will utilize over 60,000 square meters of exhibition space, creating a warm and elegant environment for visitors [1]. - Six themed exhibition areas will cater to different age groups, providing a one-stop experience for New Year festivities [1]. Group 2: Thematic Areas - The Traditional Folk Area will feature Beijing-style snacks prepared on-site and allow visitors to experience traditional crafts such as paper embroidery and cloisonné [1]. - The National Trend and Intangible Cultural Heritage Area will showcase various intangible cultural heritage skills and specialty foods, making traditional techniques accessible to visitors [1]. - The National Style Makeup Area will create immersive family photo opportunities inspired by Suzhou-style gardens, incorporating traditional games like throwing pots and guessing lantern riddles [1]. Group 3: Technology and International Elements - The Joyful Technology and International Culture Area will blend technology with cultural elements, featuring interactive robots, AI family portraits, and a high-speed train simulation, providing an immersive tech experience [1]. - The International Style Area will include cross-cultural projects like Turkish wet painting, allowing visitors to experience global New Year customs without leaving Beijing [2]. Group 4: Organizational Support - The Dadu Spring Festival Temple Fair is guided by multiple departments and associations, including the Beijing State-owned Assets Supervision and Administration Commission, the Municipal Economic and Information Bureau, the Municipal Commerce Bureau, and the Municipal Culture and Tourism Bureau [2]. - The event is organized by the Beichen Group and hosted by the Capital Convention and Exhibition Group [2].

Group 1 - The company has completed a reorganization of its board of directors and committees, with Lian Jian appointed as the chairman and executive director, marking him as the largest single shareholder [1][2] - The new board members possess strong backgrounds in finance, capital, and law, which aligns with the company's future development strategy [2] - The reorganization is seen as a significant move to optimize corporate governance, integrate advantageous resources, and enhance competitiveness, paving the way for high-quality development [2] Group 2 - The strategic direction of the company has become clearer with the new board, focusing on core cloud communication business, embracing AI, and promoting international expansion [3]

Group 1 - The company has completed a restructuring of its board of directors and committees, with Lian Jian appointed as the chairman and executive director, marking a significant change in leadership [1][2] - The new board members possess strong backgrounds in finance, capital, and law, which aligns with the company's future development strategy [2] - The restructuring is seen as a crucial step for optimizing corporate governance, integrating resources, and enhancing competitiveness, signaling the company's entry into a new phase of high-quality development [2] Group 2 - The strategic direction of the company has become clearer with the new board, focusing on core cloud communication business, embracing AI, and promoting international expansion [3]

中国创新药正步入全面收获期。在刚刚过去的2025年，我国生物医药产业创新活力迸发——全年76个创 新药获批，国产占比超八成；对外授权交易总额突破1300亿美元，创历史新高。 以仿制药起家，到转型创新药，"药王"恒瑞医药（600276）(600276.SH、01276.HK)的发展历程堪称是 中国医药产业升级的缩影。从以仿制药为营收支柱，到创新药收入占比突破60%，复出五年，孙飘扬带 领恒瑞医药转型攻坚，通过持续创新、差异化与国际化破局行业"内卷"。 2026年2月1日，恒瑞医药第九届董事会任期届满，68岁的孙飘扬会否继续担任董事长一职？恒瑞医药的 创新药全球化征程会走向怎样的新高度？ 仿制药巨头大象转身 将时间拨回2020年，那一年，恒瑞医药以超6100亿元的市值傲视群雄，稳坐A股"医药一哥"。当年，恒 瑞医药的营业收入和归母净利润分别达到277.35亿元、63.28亿元的高峰。当年，在执掌恒瑞医药近三十 年后，孙飘扬决定退居幕后，将恒瑞交给职业经理人团队。 也是在那一年，国家药品集采政策全面实施，宣告着仿制药的高利润时代终结。以仿制药起家的恒瑞医 药危机悄然浮现。 随着集采不断扩围，市场被蚕食，2021年， ...

Core Viewpoint - The company is expected to achieve a product revenue of approximately 11.9 billion yuan in 2025, maintaining a strong year-on-year growth rate of about 45% [1] - In Q4, the company achieved a product revenue of around 3.3 billion yuan, with a year-on-year increase of over 60%, validating its strong product competitiveness and commercialization system [1] - The growth is driven by the sustained performance of existing products and rapid market entry of new products, with significant contributions from non-oncology areas [1] Event Summary - On February 4, the company announced its product revenue for 2025, projecting around 11.9 billion yuan for the year and approximately 3.3 billion yuan for Q4 [1] - The Q4 revenue was influenced by the inclusion of six new drugs in the national medical insurance catalog, which led to a one-time inventory adjustment [1] Business Performance - The company has expanded its oncology pipeline to 13 products, demonstrating increasing synergy effects [2] - The successful expansion into chronic disease areas has resulted in outstanding achievements, showcasing strong growth potential across its product line [2] - Key growth drivers include products like Sintilimab, Orelabrutinib, and Lembozole, along with rapid market entry of new products such as Masitinib and Tolebrutinib [1][2] Future Outlook - The company is expected to continue leveraging its core advantages and strategic foresight to drive development across multiple disease areas, aiming to become a leading global biopharmaceutical company [2] - The company has 17 commercialized drugs, with one product under NMPA review and four new drug candidates in Phase III or critical clinical studies, alongside 15 other candidates in clinical research [2] Financial Projections - The company is projected to achieve revenues of 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan for the years 2025, 2026, and 2027, respectively, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan [2] - Following a significant global strategic partnership with Takeda, the company retains 40% rights in the U.S. for IBI363, which is expected to enhance its internationalization efforts [2]